While our study highlights that bulk transcriptome expression analysis across large cancer cohorts has both positive and negative predictive value, PSMA assessments in brain tumors may benefit further from single-cell sequencing analyses, a data modality that was not available for this study. This evidence concerns the gene FOLH1 and brain neoplasm.